| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8453816 | Lung Cancer | 2018 | 7 Pages |
Abstract
In Thailand, the first-line treatment for advanced NSCLC with TKIs conditional on EGFR test results was not cost-effective as compared with platinum doublets for all.
Keywords
UCSRCTDSAEQ5DQALYWTPICERPSAMSTDRGNMBTKINMACEACCost-effectiveness acceptability curveM−EGFRAUCPFsRandomized controlled trialCost-effectivenessInpatientprogression-free survivaloverall survivalprobabilistic sensitivity analysisWillingness to paymedian survival timeLife yearquality-adjusted life yearNSCLCNon-small cell lung cancerOutpatientNet monetary benefitconfidence intervalNetwork meta-analysisarea under the curveTyrosine kinase inhibitorhazard ratioIncremental cost-effectiveness ratioCost effectivenessDiagnosis-related groupEpidermal growth factor receptor
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Chulaporn Limwattananon, Supon Limwattananon, Onanong Waleekhachonloet, Thananan Rattanachotphanit,